{"created":"2023-05-15T16:33:17.112371+00:00","id":5457,"links":{},"metadata":{"_buckets":{"deposit":"006e9f42-58cb-4e1c-a152-d89a76a4d55b"},"_deposit":{"created_by":2,"id":"5457","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"5457"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00005457","sets":["10:11"]},"author_link":["23251","23250","23254","23256","23252","23249","23257","23255","23248","23253"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-05-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"345","bibliographicPageStart":"340","bibliographicVolumeNumber":"30","bibliographic_titles":[{"bibliographic_title":"Journal of Ocular Pharmacology and Therapeutics"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose: The benzalkonium chloride (BAK) content of tafluprost ophthalmic solution (TaprosR: tafluprost) has been reduced to balance corneal safety and preservative effectiveness (old formulation: 0.01%; new formulation: 0.001%). However, no reports have been published on its clinical effect. Therefore, we conducted a clinical research study to compare the safety of BAK-reduced tafluprost on the ocular surface with other prostaglandin ophthalmic solutions. Methods: This clinical study included 28 glaucoma patients (28 eyes) with a treatment history of latanoprost ophthalmic solution (XalatanR) or travoprost ophthalmic solution (Travatan Z R), who presented with corneal epithelial disorders. The subjects were switched to BAK-reduced tafluprost, and its effect on the ocular surface was examined after 1 and 2 months of treatment [using fluorescein staining score, hyperemia, tear film breakup time, and intraocular pressure (IOP) lowering]. Results: In all analyzed subjects (N=27), the fluorescein staining score was significantly improved after switching to BAK-reduced tafluprost (P<0.0001). Conversely, the IOP-lowering effect was not notably changed. The subjects switched from latanoprost (n=10) showed significant improvement in fluorescein staining score (P<0.05) as well as in IOP lowering (P<0.01). The subjects switched from travoprost (n=17) also showed significant improvement in fluorescein staining score (P<0.001), but without a significant change in IOP lowering. Conclusions: Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect, but also for its good corneal safety profile.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Journal of Ocular Pharmacology and Therapeutics, 30(4), pp.340-345; 2014","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Mary Ann Liebert Inc."}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1089/jop.2013.0132","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"This is a copy of an article published in the Journal of Ocular Pharmacology and Therapeutics c 2014 copyright Mary Ann Liebert, Inc.; Journal of Ocular Pharmacology and Therapeutics is available online at: http://online.liebertpub.com."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"10807683","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"15577732","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kumagami, Takeshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Wakiyama, Harumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kusano, Mao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kajiyama, Ayano"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miura, Yoko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Uematsu, Masafumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yoneda, Ai"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kurihara, Junko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Suzuma, Kiyoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kitaoka, Takashi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"JCPT30_340.pdf","filesize":[{"value":"147.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"JCPT30_340.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/5457/files/JCPT30_340.pdf"},"version_id":"ba196390-2d31-4cdd-8486-7706e359b07d"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Comparison of Corneal Safety and Intraocular Pressure?Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Comparison of Corneal Safety and Intraocular Pressure?Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions"}]},"item_type_id":"2","owner":"2","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-07-15"},"publish_date":"2014-07-15","publish_status":"0","recid":"5457","relation_version_is_last":true,"title":["Comparison of Corneal Safety and Intraocular Pressure?Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T03:04:22.170488+00:00"}